MWNA
BTAI icon

Marshall Wace North America’s BioXcel Therapeutics BTAI Stock Holding History

Marshall Wace North America’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,182
Closed -$174K – 951
2018
Q2 		$174K Sell
1,182
-2,906
-71% -$444K ﹤0.01% 1288
2018
Q1 		$670K Buy
+4,088
New +$682K ﹤0.01% 1094

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Marshall Wace North America's BTAI Position: Q3 2018 in Review

Marshall Wace North America sold out of BioXcel Therapeutics (BTAI) in Q3 2018, closing a stake of 1,182 shares — an estimated $174K sold.

Marshall Wace North America first reported a position in BTAI in Q1 2018 and held it in 2 quarters. The position peaked at $670K in Q1 2018. 19 funds tracked by Wall St. Rank hold BTAI as of Q3 2018.

  • Marshall Wace North America reported no remaining BioXcel Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Marshall Wace North America sold 1,182 BioXcel Therapeutics shares in Q3 2018, an estimated $174K.
  • Marshall Wace North America first reported a position in BioXcel Therapeutics in Q1 2018 and held it in 2 quarters.
  • Marshall Wace North America's BioXcel Therapeutics position peaked at $670K in Q1 2018.
  • 19 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2018.

Based on Marshall Wace North America's 13F filing for Q3 2018, filed 14 Nov 2018.